WO2000035466A1 - Graines d'aframomum ameliorant l'activite du penis - Google Patents

Graines d'aframomum ameliorant l'activite du penis Download PDF

Info

Publication number
WO2000035466A1
WO2000035466A1 PCT/CA1998/001165 CA9801165W WO0035466A1 WO 2000035466 A1 WO2000035466 A1 WO 2000035466A1 CA 9801165 W CA9801165 W CA 9801165W WO 0035466 A1 WO0035466 A1 WO 0035466A1
Authority
WO
WIPO (PCT)
Prior art keywords
aframomum
composition
seeds
species
ancestors
Prior art date
Application number
PCT/CA1998/001165
Other languages
English (en)
Inventor
Victor Ngoka
Neil G. Hartman
Simon Ossawa
Michel Ibea
Original Assignee
Peya Biotech Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peya Biotech Inc. filed Critical Peya Biotech Inc.
Priority to PCT/CA1998/001165 priority Critical patent/WO2000035466A1/fr
Priority to AU16578/99A priority patent/AU1657899A/en
Publication of WO2000035466A1 publication Critical patent/WO2000035466A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)

Definitions

  • the invention relates to pharmaceutical compo- sitions based on the use of "Aframomum " seeds to solve the problem of male erectile dysfunction as well as premature ejaculation in men.
  • Penile erection is a haemodynamic event under autonomic nervous control .
  • blood flow filling the vascular spaces which results in tumescence .
  • vasodilatation of the penile arteries rapidly followed by relaxation of the cavernous smooth muscle are primarily responsible for the initiation of erection (Newman and Northup, 1981, Urol . , 17:399-408) .
  • NA acetylcholine
  • ACh acetylcholine
  • ATP adenosine 5 ' -triphosphate
  • 5-HT serotonin 5-hydroxytryptamine
  • VIP vasoactive intestinal polypeptide
  • CGRP calcitonin gene-related peptide
  • NPY neuropeptide Y
  • SP substance P
  • Erectile dysfunction or impotence is common, affecting an estimated one in ten men, with prevalence much higher in certain subgroups: diabetics, smokers
  • Endocrinal causes of impotence constituting less than 10% of total causes of impotence, can be suc- cessfully treated by medical therapy. In all other causes, drug therapy has not been satisfactory and a few drugs and/or drug combinations have gained clinical acceptance.
  • These drugs are vasodilators, they include yohimbine, papaverine, papaverine and phentolamine in combination and prostaglandin El.
  • Yohimbine and phentolamine are known to be an alpha-adrenoreceptor blocker.
  • Yohimbine is available for oral use. It has first appeared to have promising value but recently, several studies revealed a marginal and non significant effect (Morales et al . , 1987, J. Urol . , 137:1168-72; Susset et al . , 1989, J " . Urol . , 141:1360-1363). Furthermore, yohimbine may induce hypertension, rashes and panic attacks. It is important to note that yohimbine is not licensed in the United Kingdom and has never been approved by the United States FDA (Jan. 1995, In La Lettre Medicale, Vol. 18, No. 20:89) .
  • Papaverine is often characterized as a non-specific vasodilator, and its cellular mechanism of action is unclear. It is an intracorporeally administered drug and its efficiency is better than yohimbine.
  • an intracavernosal injection of papaverine can produce major side effects such as prolonged painful erection. Other side effects include fibrosis and bruising at the site of injection and liver function abnormalities among others (Virag, 1982, Lancet, vol. ii:938) .
  • many patients are disenchanted with the long-term injection involved in intracavernosal pharmacotherapy, finding the tech- nique artificial, lacking in spontaneity and being time consuming.
  • PGE1 Prostaglandin El
  • One aim of the present invention is to provide a painless therapy for male erectile dysfunction as well as for premature ejaculation in male without the drawbacks of the prior art techniques .
  • composition of the present invention pro- vide a painless and safe medication to patients suffering from erectile dysfunction and premature ejaculation as well as to men wishing to improve their sexual performance .
  • Aframomum is a broad genus of plants found in the humid tropics of Africa, which includes more than 50 species known to date.
  • the Aframomum species all belong to the family of Zingrijeraceae.
  • the genus Aframomum is employed as a spice, in perfumes and dyes, and currently in the treatment of hemorrhoids in Africa where some of them are widely cultivated for their edible spicy fruit .
  • leafs are well known to be dispensed for measles and externally for leprosy, while a root decoc- tion is taken by nursing mothers to inhibit excessive lactation and to control postpartum hemorrhage.
  • Rhizomes of other species are used as ingredient for the preparation of remedy for infertility, to promote conception and the fresh fruits are used some times as tonic for sexual stimulation.
  • Several plants in the genus are also used as purgative, galactogogue and anthelmintic and as hemostatic agent. Seeds of some species are also used with leaves of Urera oblongi folia as an external treatment for tumors.
  • Senegal seeds of Aframomum melegueta are usually mixed with salt and rubbed to the interior of the mouth as treatment of sleeping sickness.
  • Antimicrobial activity have also been reported for seed constituents of Aframomum daniellii , but, no species of the genus, has ever been reported on its seed abilities to reestablish erectile function and/or to improve penile rigidity in men.
  • the invention provides a new application of Aframomum plants in improving male penile rigidity, and/or treating male erectile dysfunction and premature ejaculation.
  • a pharmaceutical composition for improving penile rigidity and/or treating erectile dysfunction, as well as premature ejaculation, of a male mammal patient which comprises: at least one type of seeds selected from the group consisting of Aframomum stipulatum, Aframomum geocarpum, Aframomum usambarence, its closely or related species, and remote ancestors thereof, mixture thereof and extracts thereof.
  • the pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier for topical or oral administration.
  • the pharmaceutical composition of the present invention is not aphrodisiac but may be used both by healthy and non-healthy men to improve penile rigidity, or to delay ejaculation.
  • the pharmaceutical composi- tion of the present invention can also be used to prevent premature ejaculation.
  • male mammal patient as used herein is intended to mean a mammal selected from the group consisting of human, equine, caprine, bovine, canine and feline.
  • healthy men as used herein is intended to mean a men which show no penile erectile dysfunction.
  • non-healthy men as used herein is intended to mean a men bearing erectile dysfunction.
  • the present invention relates to an oral or topical composition for the treatment of male erectile dysfunction which comprises Aframomum .
  • the present invention relates particularly to the Aframomum seeds ability to delay male ejaculation and to ensure full erection.
  • the pharmaceutical composition of present invention are intended for oral or topical administra- tion which constitutes one of the mam advantages of the present invention with respect to the prior art therapy.
  • composition of the present invention may optionally be used with alcoholic beverages to synergistically maintain libido, whereas successive eiaculation/reerection can easily be done for several times with constant penile rigidity.
  • any of the following Aframomum seeds may be used alone or m combination:
  • At least two of the foregoing Aframomums or the seed extracts of the foregoing Afra - momums may be used as active ingredients in the composition for improvement of penile rigidity and/or treat- ment of male erectile dysfunction and premature ejaculation.
  • Aframomum seeds may be used, which are the seeds of unnamed Aframomum consisting of the remote ancestors of the foregoing Aframomums as an active ingredient in the composition for improvement of penile rigidity and/or treatment of male erectile dysfunction and premature ejaculation.
  • Aframomum seeds are the seeds of unknown Aframomums and unknown related species as an active ingredient in the composition for improvement of penile rigidity and/or treatment of male erectile dysfunction and premature ejaculation.
  • Aframomum seeds of the present invention and the composition of the present invention are beneficial in that :
  • composition of the present invention may be used by both healthy and non-healthy men to delay penile ejaculation, and/or to increase penile rigidity.
  • the pharmaceutical composition of the present invention is characterized in that:
  • composition of the present invention can also be used in mixtures with hormones such as testosterone and/or other agents to synergistically improve the reestablishment of male penile function.
  • composition comprising the seeds of Aframomum species which contain benzenoids of molecular weight between 100 and 500, preferably para- dol , gingerol and/or shagaol in their chemical composition.
  • compositions comprising the seeds of Aframomum species which contain terpenoids of molecular weight between 100 and 600, preferably lab- dane diterpenoid in their chemical composition.
  • compositions comprising the seeds of Aframomum species which contain flavonoids or quinoids of molecular weight between 100 and 600 and/or the foregoing benzenoids or terpenoids in their chemical composition.
  • composition comprising the seeds of Aframomum geocarpum and its closely related species or ancestors .
  • composition comprising the seeds of Aframomum strobilaceum or Aframomum usambarence and their closely related species or ancestors .
  • composition comprising the seeds of the remote ancestors of Aframomum melegueta and their closely related species containing paradol, shagaol or gingerol .
  • the most preferred embodiment of the present invention relates to composition
  • composition comprising the seeds of Aframomum stipulatum and its closely related species or ancestors.
  • the preferred dosage of the composition of the present invention contains between about 0.3mg/kg to about lOmg/kg of the seeds of Aframomum species per weight of the patient, most preferably between about lmg/kg to about 6mg/kg.
  • the composition intake may be daily, twice daily or up to three times daily depending on the patient's condition.
  • the preferred pharmaceutically acceptable carrier which may be used in accordance with the present invention includes any pharmaceutically acceptable adjuvant, such as known thickening agents (natural or synthetic) or diluting agents to form a dosage form of the pharmaceutical composition which consists of a suspension of the active ingredient.
  • a pharmaceutically acceptable adjuvant such as known thickening agents (natural or synthetic) or diluting agents to form a dosage form of the pharmaceutical composition which consists of a suspension of the active ingredient.
  • thickening agents are tragacanth mucilage and colloidal silicon dioxide.
  • Diluting agents which may be used are powders and ointment for the topical application of the pharmaceutical composition.
  • other oral dosage form may be used, which include without limitation, capsules lozenges, pastilles, molded or pressed tablets, among others.
  • Aframomum stipulatum (imported from Brazzaville, Congo) are scrupulously washed with water and sterilized for 30 min. under U.V. at 254 nm. After drying, 1 mg/kg of Aframomum stipulatum seeds, properly milled are carefully encapsulated in a sterile hoad class II, Type A/B3 (The Baker Company, Sanford,
  • Systolic/Diastolic the brachial systolic pressure average versus the diastolic pressure average in mmHg. Pressure were measured each 30 min. for (2 hours before AFS intake) , (6 hours during AFS intake) , and (2 hours more after AFS intake) on a digital blood pressure meter .

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention a pour objet une composition pharmaceutique permettant d'améliorer la rigidité du pénis et/ou de traiter ou de prévenir les troubles de l'érection ainsi que l'éjaculation précoce chez l'homme. Cette composition comprend au moins des graines de l'espèce Aframomum, les espèces apparentées proches et éloignées de cette dernière, et des extraits de celle-ci. La composition selon l'invention comprend un excipient pharmaceutiquement acceptable pour des administrations par voie topique et/ou orale.
PCT/CA1998/001165 1998-12-11 1998-12-11 Graines d'aframomum ameliorant l'activite du penis WO2000035466A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/CA1998/001165 WO2000035466A1 (fr) 1998-12-11 1998-12-11 Graines d'aframomum ameliorant l'activite du penis
AU16578/99A AU1657899A (en) 1998-12-11 1998-12-11 (aframomum) seeds for improving penile activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA1998/001165 WO2000035466A1 (fr) 1998-12-11 1998-12-11 Graines d'aframomum ameliorant l'activite du penis

Publications (1)

Publication Number Publication Date
WO2000035466A1 true WO2000035466A1 (fr) 2000-06-22

Family

ID=4173337

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1998/001165 WO2000035466A1 (fr) 1998-12-11 1998-12-11 Graines d'aframomum ameliorant l'activite du penis

Country Status (2)

Country Link
AU (1) AU1657899A (fr)
WO (1) WO2000035466A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062364A1 (fr) * 2001-02-05 2002-08-15 Gbodossou Erick Vidjin Agnih Composition antivirale a base de plantes medicinales pour combattre le vih/sida
FR2821553A1 (fr) * 2001-03-05 2002-09-06 Rech S En Pharmacognosie Serp Utilisation d'un ou plusieurs shogaol (s) en tant qu'aphrodisiaque
CN103402530A (zh) * 2010-10-19 2013-11-20 K.L.R.M.公司 用于治疗勃起功能障碍的组成物及方法
WO2016181214A1 (fr) * 2015-05-13 2016-11-17 Gbodossou Erick Compositions et procédés destinés au traitement de la maladie à virus ebola

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879682A (en) * 1995-11-24 1999-03-09 Peya Biotech Inc Aframonum seeds for improving penile activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879682A (en) * 1995-11-24 1999-03-09 Peya Biotech Inc Aframonum seeds for improving penile activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. FOYERE AYAFOR ET AL.: "NOVEL BIOACTIVE DITERPENOIDS FROM AFRAMOMUM AULACOCARPOS", THE JOURNAL OF NATURAL PRODUCTS, vol. 57, no. 7, July 1994 (1994-07-01), pages 917 - 923, XP002111699 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062364A1 (fr) * 2001-02-05 2002-08-15 Gbodossou Erick Vidjin Agnih Composition antivirale a base de plantes medicinales pour combattre le vih/sida
FR2821553A1 (fr) * 2001-03-05 2002-09-06 Rech S En Pharmacognosie Serp Utilisation d'un ou plusieurs shogaol (s) en tant qu'aphrodisiaque
WO2002070069A2 (fr) * 2001-03-05 2002-09-12 Lmd Utilisation d'un ou plusieurs shogaol(s) en tant qu'aphrodisiaque
WO2002070069A3 (fr) * 2001-03-05 2003-01-03 Rech S En Pharmacognosie Serp Utilisation d'un ou plusieurs shogaol(s) en tant qu'aphrodisiaque
CN103402530A (zh) * 2010-10-19 2013-11-20 K.L.R.M.公司 用于治疗勃起功能障碍的组成物及方法
CN107537013A (zh) * 2010-10-19 2018-01-05 K·L·R·M·公司 用于治疗勃起功能障碍的组成物及方法
US10406196B2 (en) 2010-10-19 2019-09-10 K.L.R.M., Llc Compositions and methods for treating, inhibiting the onset, and slowing the progression of erectile dysfunction including naturally occurring age related erectile dysfunction
WO2016181214A1 (fr) * 2015-05-13 2016-11-17 Gbodossou Erick Compositions et procédés destinés au traitement de la maladie à virus ebola

Also Published As

Publication number Publication date
AU1657899A (en) 2000-07-03

Similar Documents

Publication Publication Date Title
Tam et al. Yohimbine: a clinical review
US6544563B2 (en) Method and composition for improving sexual fitness
US6793942B2 (en) Composition and method for treating the effects of diseases and maladies
LT4404B (lt) Vaistų formos žmogaus seksualinio atsako moduliavimui
US20020006445A1 (en) Composition and method for treating the effects of diseases and maladies
CA2563952C (fr) Utilisations de glycosides pregnanes pour le traitement ou la gestion de l'obesite, de troubles associes a l'obesite et d'autres desordres
US20020128273A1 (en) Composition and method for treating the effects of diseases and maladies
US5879682A (en) Aframonum seeds for improving penile activity
WO2006002096A2 (fr) Faibles doses de l-citrulline pour traiter des maladies
US20010044411A1 (en) Composition and method for treating the effects of diseases and maladies
KR100567154B1 (ko) 트라마돌을 함유하는 약제학적 배합물
JP2003534286A (ja) 勃起障害症状改善のために、刺激物質の活性成分としてプロアントシアニジン、一酸化窒素源としてｌアルギニン又はその塩の使用
KR20150007493A (ko) 전립선 비대증 예방 또는 치료용 약학적 조성물 및 이의 제조방법
WO2000035466A1 (fr) Graines d'aframomum ameliorant l'activite du penis
US20040137081A1 (en) Attaining sexual wellness and health of the sexual vascular system with proanthocyanidins
JP5602696B2 (ja) プロアントシアニジンによる性的機能及び性器血管系の改善
US7371415B1 (en) Method and composition for improving sexual fitness
WO2005049053A1 (fr) Composition comprenant un compose de magnesium et/ou un sel de magnesium ameliorant les dysfonctionnements sexuels
WO2012056475A2 (fr) Composition pour améliorer la santé sexuelle
JP2007501856A (ja) 片頭痛治療薬
EP1284744B1 (fr) Combinaison antimigraine comprenant des extraits de sapindus et d'emblica
KR101846529B1 (ko) 발기력을 포함하는 남성 성기능 개선을 위한 조성물
KR20050104091A (ko) 골성장촉진활성을 갖는 엘루테로사이드 이 및 이를함유하는 기능성 식품 및 약학적 제제
KR20060026938A (ko) 골성장 촉진활성을 갖는 엘루테로사이드 ｅ를 함유하는약학조성물
US20240050508A1 (en) Neem for treatment of rls

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase